Container Top
Homes   Jobs   Cars   Shopping
Search

Events Calendar

EVENT SEARCH:

In This Section


Most Read Stories


Blogs:


Pets:
Dogs' Bark: Not fair! Study shows pups get jealous

The Heldenfiles:
Who Will Get the Michael Media Treatment Next?

Patrick McManamon:
More on Varejao

Akron Zips:
Opponent outlook: Kent State

Browns Bulletin:
Quick thought on Browns rookies

Tribe Matters:
Wedge challenges relievers

Cleveland Browns:
Stallworth test showed marijuana

Kent State Sports:
Men's Basketball Scheduling update

Cleveland Cavaliers:
Andy’s Signed According to ESPN

All Da King's Men:
Does Medicare Have Lower Administrative Costs ?

Blog of Mass Destruction:
CIA Did Mislead Congress

Akron Law Café:
Breaking Story: CIA Lied to Congress about Secret Program

Varsity Letters:
East basketball update

See Jane Style:
Oh Baby!

Car Chase:
Where do We Go from Here?

Let's Talk Real Estate:
Closings….Not the Good Kind!

Ohio Travels with Betty:
Margy inquires-when is a Taste of Hudson?

Sound Check:
LeVert II live performance Saturday night — "Dedication" album due July 13,

HRLite House:
DDI One of Best Places to Work

Akron Gamer:
First 24 'Guitar Hero 5' songs announced

Defense department grants to spur research in tissue regeneration

By Tracy Wheeler
Beacon Journal medical writer

The Cleveland Clinic will help lead a consortium of institutions in finding new ways to heal soldiers severely wounded in battle, the U.S. Department of Defense announced this afternoon.

The defense department is committing $85 million to create a new Armed Forces Institute for Regenerative Medicine (AFIRM).

The Cleveland Clinic, along with Rutgers University, will head a consortium of 15 research centers that includes Case Western Reserve University, University Hospitals Case Medical Center, the Massachusetts Institute of Technology, Harvard Medical School and the Mayo Clinic, among others.

A second consortium will be led by the University of Pittsburgh and Wake Forest University.

The two research efforts will each receive $42.5 million in grants. The Clinic will receive a $10 million slice of the grant.

The defense department's goal is to push forward research in the areas of tissue regeneration (using a patient's own cells to grow new bone, muscle, tissue, nerves or blood vessels) and transplantation (using donated limbs to replace those lost in battle or donated facial tissue to replace soldiers' faces severely damaged by fire or explosion).

Research in these areas is already taking place — much of it in Cleveland, said Dr. George Muschler, director of the Clinic's clinical tissue-engineering center and co-director of AFIRM.

The goal of the defense department grants is to push the research to make ''dramatic strides in the next one to five years,'' Muschler said.

''The department of defense was very clear that they were not looking for 'pie in the sky' stuff, not things that might be possible 20 years from now,'' he said. ''There are people who need help now. . . . We need to take the things we can do realistically and focus on those first.''

That would include using a patient's own stem cells to regrow bone, muscle and blood vessels lost in an explosion and using limbs from deceased donors to replace hands, feet, arms or legs lost in war.

''This is already a clinical reality,'' said Dr. Maria Siemionow, the Clinic's head of plastic surgery research. ''Fifty patients worldwide have already had hand transplants. Three patients have had partial face transplants.''

The problem with such transplantations, though, is the risk of rejection by the recipient's immune system. Siemionow's research will focus on novel therapies to quell immune response, without forcing the patient to be on immunosuppresive drugs for a lifetime.


Tracy Wheeler can be reached at 330-996-3721 or tawheeler@thebeaconjournal.com.

The Cleveland Clinic will help lead a consortium of institutions in finding new ways to heal soldiers severely wounded in battle, the U.S. Department of Defense announced this afternoon.

The defense department is committing $85 million to create a new Armed Forces Institute for Regenerative Medicine (AFIRM).

The Cleveland Clinic, along with Rutgers University, will head a consortium of 15 research centers that includes Case Western Reserve University, University Hospitals Case Medical Center, the Massachusetts Institute of Technology, Harvard Medical School and the Mayo Clinic, among others.

A second consortium will be led by the University of Pittsburgh and Wake Forest University.

The two research efforts will each receive $42.5 million in grants. The Clinic will receive a $10 million slice of the grant.

The defense department's goal is to push forward research in the areas of tissue regeneration (using a patient's own cells to grow new bone, muscle, tissue, nerves or blood vessels) and transplantation (using donated limbs to replace those lost in battle or donated facial tissue to replace soldiers' faces severely damaged by fire or explosion).

Research in these areas is already taking place — much of it in Cleveland, said Dr. George Muschler, director of the Clinic's clinical tissue-engineering center and co-director of AFIRM.

The goal of the defense department grants is to push the research to make ''dramatic strides in the next one to five years,'' Muschler said.

''The department of defense was very clear that they were not looking for 'pie in the sky' stuff, not things that might be possible 20 years from now,'' he said. ''There are people who need help now. . . . We need to take the things we can do realistically and focus on those first.''

That would include using a patient's own stem cells to regrow bone, muscle and blood vessels lost in an explosion and using limbs from deceased donors to replace hands, feet, arms or legs lost in war.

''This is already a clinical reality,'' said Dr. Maria Siemionow, the Clinic's head of plastic surgery research. ''Fifty patients worldwide have already had hand transplants. Three patients have had partial face transplants.''

The problem with such transplantations, though, is the risk of rejection by the recipient's immune system. Siemionow's research will focus on novel therapies to quell immune response, without forcing the patient to be on immunosuppresive drugs for a lifetime.


Tracy Wheeler can be reached at 330-996-3721 or tawheeler@thebeaconjournal.com.



Story tools

Email  Email   Print  Print   Save  Save   Reprint  Reprint   Popular  Most Popular   Reprint  Subscribe

Share this story

AddThis Social Bookmark Button
















Most Commented Stories